

CURRICULUM VITAE

Eirini I. Rigopoulou

Associate Professor in Medicine/Consultant Physician/Hepatologist

February 2016

Contents	page no
Personal details	p 3
Academic Qualifications	p 3
Clinical and Academic Appointments	p 3-4
Scholarships/Awards	p 5
Clinical experience	p 5-6
Teaching experience	p 6-7
Research experience	p 7-8
Supervision of PhD students	p 9
Publications in peer review journals, citations	p 9-21
Chapters in books	p 21
Published abstracts	p 21-25
Citations	p 25-26
Grants/ financial support	p 27
Reviewer in peer review journals	p 27
Member of societies	p 28
Administrative work	p 28
Member of organising committees of congresses/ conferences/symposia	p 28-29
Presentations in international meetings	p 29-34

PERSONAL INFORMATION

Name	Eirini Rigopoulou
Date of birth	12 th December 1965
Place of birth	Athens, Greece
Nationality	Greek
Familial status	married, 1 child
Address (home)	Rodou str, 55 Larissa, Greece Tel: +30 2410-555138 Mobile: +30 6937376275
Address (work)	University of Thessaly Medical School Mezourlo 41110, Larissa, Greece Tel: +30 241350 2801 Fax: +30 241350 1557
Email:	eirigopoulou@med.uth.gr , erigopoulou@yahoo.co.uk
General Medical Council Registration number	Registration No: 4475536
Spoken languages	Greek, English, German, French

ACADEMIC QUALIFICATIONS

December 1989	MD (Ptychion Iatrikes), Kapodistrian University of Athens, Greece (grade: very well).
November 1997	Specialty of Internal Medicine
June 2002	PhD, Kapodistrian University of Athens, Greece (grade: excellent)

PRESENT CLINICAL AND ACADEMIC APPOINTMENT

October 2007- to today	Assistant Professor of Medicine (tenure post from June 2011), Consultant Physician/Hepatologist, Department of Medicine, University of Thessaly, Medical
-------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------

School Greece (Director: Professor G.N. Dalekos)

PAST CLINICAL ACADEMIC APPOINTMENTS

- February 2003- October 2007** Lecturer in Medicine, Consultant Physician/Hepatologist, Department of Medicine, University of Thessaly, Medical School, Greece (Director: Professor N. Stathakis)
- March 2001- February 2003** Consultant Physician/Hepatologist, Liver Unit, Athens Medical Center (Director: Prof. D. Tsantoulas)
- December 1998- March 2001** Clinical Research Fellow, Institute of Hepatology, University College London Medical School, Supervisor: Professor N.V. Naoumov, Director: Professor R. Williams
- February 1999- December 1999** Clinical Fellow, Liver Unit Cromwell Hospital (Director: Professor R. Williams)
- January 1998- November 1998** Clinical Fellow, Liver and Liver Transplant Unit, Addenbrooke's Hospital, Cambridge, U.K (Director: Professor GJM Alexander)
- September 1992-September 1997** Specialty in Internal Medicine (Senior House Officer and Specialist Registrar), 1st Department of Internal Medicine, Sismanoglion District Hospital, Athens, Greece (Director: Prof. D. Tsantoulas)
- May 1990- May 1992** Community work at the District Medical Practice in Stavros, Ithaka, Greece
- 1–31 August 1988** Department of Pediatrics, Universitäts-Kinderklinik, Staatliches Luitpold-Krankenhaus, Würzburg, Germany, Director: Prof. Dr. D. Gekle (part of an international students exchange program)

August - September 1987

Internal Medicine/ Gastroenterology
Medizinische Universitäts Klinik (Ludolf-
Krehl-Klinik), Heidelberg, Germany,
Director: Prof. Dr Commerel (part of an
international students exchange
programm)

SCHOLARSHIPS/AWARDS

March 1997: Scholarship from the Hellenic Association for the Study of the Liver for postgraduate studies in Hepatology (Addenbrook's Hospital, University of Cambridge, UK)

September 1999-January 2001: Scholarship from Alexander S. Onassis Public Benefit Foundation to carry out research in Hepatology (Institute of Hepatology, UCL, UK)

September 2000: BASL Travel Bursary Award

Herakleitos General Secretariat for Research & Technology (GSRT), Hellenic Ministry of Development: Support for the research of Dr M Bakarozis

Herakleitos GSRT, Hellenic Ministry of Development: Support for the research of Dr A Koutsoumpas

CLINICAL EXPERIENCE

General internal medicine

As a consultant physician since February 2003, when I joined the Department of Medicine of the University Hospital of Larissa, I was responsible in rotation (1:6 rota) with my consultant colleagues for the acute medical take assigned to the University Department of Medicine. The University Hospital of Larissa acts as a referral hospital for the whole region of Thessaly (Central Greece), with a population of around 1 million inhabitants.

Since I have become Assistant Professor, I had direct supervision of one chief resident (registrar), four senior house officers and 2 consultants with whom "post take" rounds were undertaken in general medical in-patients. These also function as post-graduate training sessions.

During my 5 years as a resident in internal medicine (SHO and Specialist Registrar post) in a district general hospital (Sismanoglou Hospital, Athens), I gained experience in all aspects of Internal Medicine and covered a 1:3 to 1:4 rota. I spent 8 months as a registrar in the ITU, where I received training in the care of medical and surgical patients with multi-organ failure requiring artificial ventilation, invasive haemodynamic monitoring and haemofiltration. I was one of the registrars covering the unit, which had 10 beds, and looked after patients

following general surgical procedures, as well general surgical/medical ITU cases.

Hepatology

In my present appointment as Assistant Professor of Medicine I am one of the 3 consultants, alongside with Professor G.N. Dalekos who are responsible for the care of patients with all aspects of acute or chronic liver diseases.

The Liver Unit is an intergrated servise within the Department of Medicine and provides in-patients and out-patients services. It acts as a referral center for the whole region of Thessaly.. I have one general hepatology clinic per week. I have participated in numerous clinical trials.

In my training, I had the opportunity to gain experience in the management of all aspects of liver disease in in- and out-patients. During this period I participated in several clinical trials involving the management of patients with viral hepatitis.

As part of my training in Hepatology and Transplantation I spent one year at the Addenbrook's Hospital in Cambridge as a Clinical Fellow (Head: Professor G Alexander). I gained experience in the management of patients with acute and acute-on chronic-liver failure and in the management of complications post liver transplantation.

Subsequently, from November 1998 to Jauary 2001 as a Clinical Fellow at the Institute of Hepatology (University College London Medical School, Head: Professor NV Naoumov, Director: Professor Roger Williams) I participated in all aspects of clinical and educational activities, including radiology and histology sessions, audits, research in progress and journal clubs. I also participated in out-patients clinic and performed on weekly basis liver biopsies (Middlesex Hospital). From February 1999 to December 1999, I worked at the Liver Unit of Cromwell Hospital, where I was responsible for in-patients, who were under the care of Professor R. Williams. This work provided me with additional experience in advanced liver disease (acute liver failure, end strage liver disease, and hepatocellular carcinoma). Additionally I participated in the living-related liver transplantation programm that was active during this period at Cromwell hospital.

UNDERGRADUATE AND POST-GRADUATE TEACHING EXPERIENCE AND MEDICAL EDUCATION

Undergraduate Teaching Responsibilities

I have been involved with undergraduate clinical training throughout my medical career. Since 2003, initially as a Lecturer and subsequently as Assistant Professor of Medicine I was actively involved in teaching medical students in the clinical years (3rd, 4th, 6th year). I was assigned the tutorship for the teaching of "Internal Medicine" in 3rd year medical students during the academic year

2009-2010 and academic year 2014-15. I am a regular examiner for 3rd, 4th and 6th year written and oral medical exams in Internal Medicine.

Postgraduate Teaching Responsibilities

I am involved in post-graduate teaching and training since 2003. This includes the supervision and teaching of registrars in clinical skills, as well as various aspects of clinical research. From 2008-2015, I co-coordinated the educational program of the Department of Medicine of the University of Thessaly, which included case presentations, literature and research update on a weekly basis. During the last 2 years I have participated as examiner in the final written and oral examination for the accreditation of the speciality of Internal Medicine.

RESEARCH EXPERIENCE

- 1) Study of the immunopathogenesis of viral hepatitis B and C and of the immunomodulatory properties of agents such as ribavirin, IL-10, IL-12. This work was mainly conducted at the Institute of Hepatology, UCL, under the supervision of Professor N.V. Naoumov. Part of this work was presented as a PhD thesis in 2002 at the Kapodistrian University of Athens Medical School with the title: Study of parameters of immune responses in patients with chronic hepatitis C.
- 2) Study of the role of molecular mimicry in the induction of autoantibodies in autoimmune liver diseases and especially in patients with PBC. These projects were undertaken in collaboration with the group directed by Professor Diego Vergani, initially at the Institute of Hepatology, UCL and subsequently at the Institute of Liver Studies, King's College London.
- 3) Upon my return to my native country and following my academic appointment in the University of Thessaly Medical School, I continued my research on the study of viral hepatitis (epidemiology, pathogenesis, treatment) and autoimmune liver disease (oxidative stress, autoantibodies, immunopathogenesis). A number of these studies have been performed in collaboration with other Faculties of the University of Thessaly and renowned Clinical and Research Centers of Excellence in UK, Germany, Italy, and Spain (see analytical list of Collaborations).
- 4) Clinical trials:

As a Registrar (Sismanoglion Hospital, Athens), I participated in 6 trials involving mainly treatment of patients with chronic HBV, HCV and hepatocellular carcinoma.

When I was at the Institute of Hepatology (UCL), I was involved in a randomised pilot study comparing lamivudine monotherapy with a combination of lamivudine plus recombinant hIL-12 at two doses (publication No 22).

London (October 2002): I also participated in a consensus meeting from 13 European countries in order to reach Europe-wide consensus guidelines for prevention of transmission of HBV and HCV from Health Care Workers to patients.

February 2001-February 2003 (Athens Medical Center): During this period, I participated as a sub-investigator in the following international trials:

1. An open, randomized, multicentre Phase I/II study to evaluate the safety and therapeutic efficacy of SmithKline Beecham Biologicals Immunotherapeutics candidate Hepatitis B Pharmaccine, administered together with Lamivudine versus Lamivudine alone, in adult patients with HBeAg negative, anti-HBe antibody positive chronic hepatitis B
2. Multicenter open label expanded access program of Peg-Interferon alpha-2a (Ro 25-8310) and combination therapy with Rabivirin (Ro 20-9963) in patients with chronic hepatitis C

February 2003- today (University of Thessaly): I have participated in the following Greek and International clinical trials as sub-investigator:

1. A multicenter randomised study comparing the efficacy of adefovir dipivoxil vs. pegylated interferon-alfa-2a plus placebo vs. adefovir dipivoxil plus pegylated interferon-alfa-2a for the treatment of chronic delta hepatitis (Co-ordinators: Professor MP Manns και Professor Cihan Yurdaidin). (Publication No 55)
2. A multicenter, double blinded study in patients with chronic hepatitis C who are non-responders to prior peginterferon-aor peginterferon-a+ribavirin therapy comparing treatment with Thymosin a1+peginterferon-a-2a+ribavirin with peginterferon-a-2a+ribavirin+ placebo (08/2006-12/2008; Co-ordinator: Professor Mario Rizzetto). During the trial an audit was conducted from independent authority with excellent results.
3. A multicenter, double blinded study on Tenofovir Versus Hepsera (Adefovir) in the treatment of naïve patients with chronic HBeAg Negative Chronic Hepatitis B. During the trial an audit was conducted from independent American company with excellent results.
4. Hellenic multicenter phase IV clinical trial (23 centers) entitled: «prognostic parameters of long-term response in HBeAg negative chronic hepatitis B patients receiving Pegylated-IFN-a 2a (Co-ordinators: Professor E. Akriviadis and Ass. Professor I. Goulis).

SUPERVISION OF PhD STUDENTS (February 2003- today)

1. First supervisor of 2 PhD students
2. Member of the tripartite supervisors committee of 13 PhD students
3. Internal examiner in 8 PhD viva examinations

PUBLICATIONS IN PEER REVIEW JOURNALS

Analysis of publications in peer review journals:

Original articles: 52

Review articles: 25

Case reports: 3

Letters to the Editor: 10

Editorials: 2

Publications in journals with high impact factor (IF):

- 14 publications in journals with IF>10: 14
- 11 publications in journals with IF>5
- 21 publications in journals with IF>3

List of Publications:

1. Shang D, Lin YH, **Rigopoulou I**, Chen B, Alexander GJ, Allain JP. Detection of TT virus DNA in patients with liver disease and recipients of liver transplant. **J Med Virol.** 2000; 61(4):455-61 (original article).
IF(2014):2.347
2. Evans PC, Smith S, Hirschfield G, **Rigopoulou E**, Wreghitt TG, Wight DG, Taylor CJ, Alexander GJ. Recipient HLA-DR3, tumour necrosis factor-alpha promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are interrelated risk factors for chronic rejection of liver grafts. **J Hepatol.** 2001; 34(5):711-5 (original article).
IF(2014):11.336
3. Lau GK, Suri D, Liang R, **Rigopoulou EI**, Thomas MG, Mullerova I, Nanji A,

Yuen ST, Williams R, Naoumov NV. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. **Gastroenterology**. 2002; 122(3):614-24 (original article).

IF(2014):16.716

4. Gunson RN, Shouval D, Roggendorf M, Zaaier H, Nicholas H, Holzmann H, de Schryver A, Reynders D, Connell J, Gerlich WH, Marinho RT, Tsantoulas D, **Rigopoulou E**, Rosenheim M, Valla D, Puro V, Struwe J, Tedder R, Aitken C, Alter M, Schalm SW, Carman WF; European Consensus Group. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. **J Clin Virol**. 2003; 27(3):213-30 (original article).
IF(2014):3.016
5. Bogdanos DP, Baum H, Grasso A, Okamoto M, Butler P, Ma Y, **Rigopoulou E**, Montalto P, Davies ET, Burroughs AK, Vergani D. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. **J Hepatol**. 2004; 40(1):31-9 (original article).
IF(2014):11.336
6. Bogdanos DP, Baum H, Butler P, **Rigopoulou EI**, Davies ET, Ma Y, Burroughs AK, Vergani D. Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. **Dig Liver Dis**. 2003; 35(11):801-5 (original article).
IF(2014):2.963
7. Bogdanos DP, Lenzi M, Okamoto M, **Rigopoulou EI**, Muratori P, Ma Y, Muratori L, Tsantoulas D, Mieli-Vergani G, Bianchi FB, Vergani D. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. **Int J Immunopathol Pharmacol**. 2004; 17(1):83-92 (original article).
IF (2014): 1.617
8. Zachou K, **Rigopoulou E**, Liaskos C, Patsiaoura K, Makri E, Stathakis N, Dalekos GN. Primary biliary cirrhosis presented as peripheral eosinophilia in asymptomatic women with or without elevated alkaline phosphatase. **Eur J Gastroenterol Hepatol**. 2004; 16(4):425-8 (original article).
IF(2014):2.253
9. Abbott WG, **Rigopoulou E**, Haigh P, Cooksley H, Mullerova I, Novelli M, Winstanley A, Williams R, Naoumov NV. Single nucleotide polymorphisms in the interferon-gamma and interleukin-10 genes do not influence chronic hepatitis C severity or T-cell reactivity to hepatitis C virus. **Liver Int**. 2004; 24(2):90-7 (original article).
IF(2014):4.850
10. Bogdanos DP, Pares A, Baum H, Caballeria L, **Rigopoulou EI**, Ma Y, Burroughs AK, Rodes J, Vergani D. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in

- Spanish but not British patients with primary biliary cirrhosis. **J Autoimmun.** 2004; 22(4):353-62 (original article).
IF(2014):8.41
11. **Rigopoulou EI**, Dalekos GN. Anti-sp100 antibodies in primary biliary cirrhosis. **Scand J Gastroenterol.** 2004; 39(4):406-7 (letter).
IF(2014):2.361
 12. Georgiadou SP, Zachou K, **Rigopoulou E**, Liaskos C, Mina P, Gerovasilis F, Makri E, Dalekos GN. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases. **J Viral Hepat.** 2004; 11(4):358-65 (original article).
IF (2014):3.909
 13. Stefanidis I, Zervou EK, Rizos C, Syrganis C, Patsidis E, Kyriakopoulos G, Sdrakas L, Tsianas N, **Rigopoulou EI**, Liakopoulos V, Dalekos GN. Hepatitis E virus antibodies in hemodialysis patients: an epidemiological survey in central Greece. **Int J Artif Organs.** 2004; 27(10):842-7 (original article).
IF (2014):0.962
 14. Zachou K, **Rigopoulou E**, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. **J Autoimmune Dis.** 2004; 1(1):2 (review).
IF (2014):-
 15. Tsikrikoni A, Kyriakou DS, **Rigopoulou EI**, Alexandrakis MG, Zachou K, Passam F, Dalekos GN. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. **J Hepatol.** 2005; 42(3):393-9 (original article).
IF(2014): 11.336
 16. **Rigopoulou EI**, Davies ET, Pares A, Zachou K, Liaskos C, Bogdanos DP, Rodes J, Dalekos GN, Vergani D. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. **Gut.** 2005; 54(4):528-32 (original article).
IF(2014):14.66
 17. Liaskos C, **Rigopoulou E**, Zachou K, Georgiadou S, Gatselis N, Papamihali R, Dalekos GN. Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. **J Autoimmun.** 2005; 24(3):251-60 (original article).
IF (2014): 8.41
 18. **Rigopoulou EI**, Abbott WG, Haigh P, Naoumov NV. Blocking of interleukin-10 receptor--a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. **Clin Immunol.** 2005; 117(1):57-64 (original article).
IF(2014):3.672
 19. **Rigopoulou EI**, Stefanidis I, Liaskos C, Zervou EK, Rizos C, Mina P, Zachou K, Syrganis C, Patsidis E, Kyriakopoulos G, Sdrakas L, Tsianas N, Dalekos GN.

HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: results from five hemodialysis units in central Greece. **J Clin Virol.** 2005; 34(1):81-5 (original article).

IF(2014):3.016

20. Bogdanos DP, Baum H, Okamoto M, Montalto P, Sharma UC, **Rigopoulou EI**, Vlachogiannakos J, Ma Y, Burroughs AK, Vergani D. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. **Hepatology.** 2005; 42(2):458-65 (original article).

IF (2014):11.055

21. Zachou K, **Rigopoulou EI**, Tsikrikoni A, Alexandrakis MG, Passam F, Kyriakou DS, Stathakis NE, Dalekos GN. Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. **J Autoimmun.** 2005; 25(4):283-8 (original article).

IF (2014):8.41

22. **Rigopoulou EI**, Suri D, Chokshi S, Mullerova I, Rice S, Tedder RS, Williams R, Naoumov NV. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. **Hepatology.** 2005; 42(5):1028-36 (original article).

IF(2014):11.055

23. Stefanidis I, Liakopoulos V, **Rigopoulou EI**, Dalekos GN. Diagnostic discordance for hepatitis C virus infection in hemodialysis: correlations with clinical and laboratory features. **Am J Kidney Dis.** 2005; 46(5):992-3 (letter).

IF(2014):5.9

24. Tzovaras N, Stefos A, Georgiadou SP, Gatselis N, Papadamou G, **Rigopoulou E**, Ioannou M, Skoularigis I, Dalekos GN. Reversion of severe hepatopulmonary syndrome in a non cirrhotic patient after corticosteroid treatment for granulomatous hepatitis: a case report and review of the literature. **World J Gastroenterol.** 2006; 12(2):336-9 (case report).

IF (2014):2.369

25. Zachou K, Liaskos C, **Rigopoulou E**, Gabeta S, Papamichalis P, Gatselis N, Georgiadou S, Dalekos GN. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. **Clin Immunol.** 2006; 119(2):203-12 (original article).

IF(2014):3.672

26. Zografos TA, **Rigopoulou EI**, Liaskos C, Togousidis E, Zachou K, Gatselis N, Germanis A, Dalekos GN. Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. **J Hepatol.** 2006; 44(5):848-55 (original article).

IF (2014):11.336

27. **Rigopoulou EI**, Georgiadou SP, Barbanis S, Dalekos GN. Lack of association

- between appendectomy and primary biliary cirrhosis. **Scand J Gastroenterol.** 2006; 41(5):573-6 (original article).
IF (2014):2.361
28. Bogdanos DP, Liaskos C, **Rigopoulou EI**, Dalekos GN. Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: revealing the unforeseen **Clin Chim Acta.** 2006; 373(1-2) (letter).
IF (2014):2.824
29. Bogdanos DP, **Rigopoulou EI**. Self-mimicking autoimmune domains of hepatitis C virus core antigen. **Vaccine.** 2006; 24(37-39):6173-4 (letter).
IF(2014):3.624
30. Bogdanos DP, **Rigopoulou EI**. Viral/self-mimicry and immunological cross-reactivity as a trigger of hepatic C virus associated autoimmune diabetes. **Diabetes Res Clin Pract.** 2007; 77(1):155-6 (letter).
IF (2014): 2.538
31. Dalekos GN, Makaritsis K, **Rigopoulou EI**. Redesigning training for internal medicine. **Ann Intern Med.** 2006; 145(11):865 (letter).
IF(2014):17.810
32. **E.I. Rigopoulou**, W. G.H. Abbott, R. Williams and N. V. Naoumov. Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. **Antiviral Research** 2007 Jul;75(1):36-42 (original article).
IF (2014):3.938
33. N.K. Gatselis, **E. Rigopoulou**, A. Stefos, M. Kardasi and G.N. Dalekos. Risk factors associated with HCV infection in semi-rural areas of central Greece. **Eur J Intern Med** 2007; 18: 48-55 (original article).
IF (2014):2.891
34. **E. I. Rigopoulou**, M. Mytilinaiou, O. Romanidou, C. Liaskos and G. N. Dalekos. Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. Journal: **Journal of Autoimmune Diseases** 2007 Feb 4;4:2 (original article).
IF (2014):-
35. **E.I. Rigopoulou**, D.P. Bogdanos, G. Dalekos. How common are connective tissue disorders in patients with autoimmune hepatitis? **Sem Arthritis Rheum** 2007 Apr;36(5):332 (letter).
IF (2014):3.925
36. C. Liaskos, D.P. Bogdanos, **E.I. Rigopoulou**, G.N. Dalekos. Development of anti-mitochondrial antibodies in patients with autoimmune hepatitis: an art of facts or an artifact? **J Gastroenterol Hepatol** 2007; 22(3):454-5 (letter).
IF(2014):3.504
37. N.K. Gatselis, A. Stefos, C. Gioti, **E.I. Rigopoulou** and G.N. Dalekos_ Primary biliary cirrhosis and Henoch-Schonlein purpura: Report of two cases and review

of the literature. **Liver International** 2007 Mar;27(2):280-3 (review)

IF (2014):4.850

38. **E. I. Rigopoulou**, D-P. Bogdanos, C. Liaskos, A. Koutsoumpas, H. Baum, D. Vergani, G. N. Dalekos Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. **Clinica Chemica Acta** 2007; May 1;380(1-2):118-21 (original article).
IF (2014):2.824
39. Gabeta S, Norman GL, Liaskos C, Papamichalis PA, Zografos T, Garagounis A, **Rigopoulou EI**, Dalekos GN. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. **J Clin Immunol.** 2007 Jul;27(4):378-87 (original article).
IF (2014): 3.184
40. Bogdanos DP, Liaskos C, Pares A, Norman G, **Rigopoulou EI**, Caballeria L, Dalekos GN, Rodes J, Vergani D. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. **Hepatology.** 2007 Jun;45(6):1583 (letter).
IF (2014):11.055
41. Papamichalis PA, Zachou K, Koukoulis GK, Veloni A, Karacosta EG, Kypri L, Mamaloudis I, Gabeta S, **Rigopoulou EI**, Lohse AW, Dalekos GN. The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. **J Autoimmune Dis.** 2007 Jun 29;4:3 (original article).
IF (2014):-
42. **Rigopoulou EI**, Davies ET, Bogdanos DP, Liaskos C, Mytilinaiou M, Koukoulis GK, Dalekos GN, Vergani D. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. **Liver Int.** 2007 Nov;27(9):1226-31 (original article).
IF (2014):4.850
43. Zografos TA, Liaskos C, **Rigopoulou EI**, Togousidis E, Makaritsis K, Germenis A, Dalekos GN. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. **Am J Gastroenterol.** 2008 Mar;103(3):605-14 (original article).
IF (2014):10.755
44. Tsikrikoni A, **Rigopoulou EI**, Zachou K, Liaskos C, Kyriakou D, Dalekos GN. Bone marrow findings in patients with autoimmune liver diseases. **J Gastroenterol Hepatol.** 2008 Aug;23(8 Pt 2):e416-21 (original article).
IF(2014): 3.504
45. **Rigopoulou EI**, Dalekos GN. Autoimmune hepatitis: of host and pathogen. **Hepatology.** 2008 Jun;47(6):2147-8 (letter).

IF(2014):11.055

46. Gabeta S, Norman GL, Gatselis N, Liaskos C, Papamichalis PA, Garagounis A, Zachou K, **Rigopoulou EI**, Dalekos GN. IgA Anti-b2GPI Antibodies in Patients with Autoimmune Liver Diseases. **J Clin Immunol**. 2008; 28(5):501-11 (original article).
IF (2014): 3.184
47. **Rigopoulou EI** and Dalekos GN, Molecular diagnostics of primary biliary cirrhosis. *Expert Opinion on Medical Diagnosis* 2008; 2(6): 621-634 (review).
IF (2014)= -
48. Georgiadou SP, Zachou K, Liaskos C, Gabeta S, **Rigopoulou EI**, Dalekos GN. Occult hepatitis B virus infection in patients with autoimmune liver diseases. **Liver Int**. 2009;29(3):434-42 (original article).
IF (2014):4.850
49. Stefos A, Gatselis N, Zachou K, **Rigopoulou E**, Hadjichristodoulou C, Dalekos GN. Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. **Eur J Intern Med**. 2009;20(1):35-43 (original article).
IF (2014):2.891
50. Liaskos C, Norman GL, Moulas A, Garagounis A, Goulis I, **Rigopoulou EI**, Dalekos GN. Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis. **Clin Chim Acta**. 2010;411(5-6):411-5 (original article).
IF (2014):2.824
51. Mina P, Georgiadou SP, Rizos C, Dalekos GN, **Rigopoulou EI**. Prevalence of occult hepatitis B virus infection in haemodialysis patients from central Greece. **World J Gastroenterol**. 2010;16(2):225-31 (original article).
IF (2014):2.369
52. **Rigopoulou EI**, Dalekos GN. Can mathematical models be useful in clinical hepatology? **Liver Int**. 2010 May;30(5):637-8 (editorial)
IF (2014):4.850
53. Gatselis NK, Zachou K, Papamichalis P, Koukoulis GK, Gabeta S, Dalekos GN, **Rigopoulou EI**. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score? **Dig Liver Dis**. 2010 Nov;42(11):807-12 (original article).
IF (2014):2.963
-
54. Zachou K, Gatselis N, Papadamou G, **Rigopoulou EI**, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. **J Hepatol**. 2011

Sep;55(3):636-46. (original article).

IF (2014): 11.336

55. Wedemeyer H, Yurdaydın C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H, Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP; HIDIT Study Group.
Collaborators: Akarca US, Berg T, Böcher W, Bohle H, Buggisch P, Cornberg M, Ersöz G, Feyerabend S, Hinrichsen H, Manok M, Häussinger D, Herzog W, Hofmann WP, Plein K, Hardt H, Porst H, Mederacke I, **Rigopoulou I**, Şentürk H, Tabak F, v Wagner EK, Yalçın K. Peginterferon plus adefovir versus either drug alone for hepatitis delta. **N Engl J Med**. 2011 Jan 27;364(4):322-31 (original article)
IF (2014): 55.873
56. Smyk D, Mytilinaïou MG, **Rigopoulou EI**, Bogdanos DP. PBC triggers in water reservoirs, coal mining areas and waste disposal sites: from Newcastle to New York. **Dis Markers**. 2010;29(6):337-44. (review)
IF (2014): 1,563
57. Smyk D, **Rigopoulou EI**, Baum H, Burroughs AK, Vergani D, Bogdanos DP. Autoimmunity and Environment: Am I at risk? **Clin Rev Allergy Immunol**. 2012; 42: 199-212 (review)
IF (2014): 5.463
58. Koutsoumpas A, Polymeros D, Tsiamoulos Z, Smyk D, Karamanolis G, Triantafyllou K, **Rigopoulou EI**, Forbes A, Vergani D, Bogdanos DP, Ladas SD. Peculiar antibody reactivity to human connexin 37 and its microbial mimics in patients with Crohn's disease. **J Crohns Colitis**. 2011 Apr;5(2):101-9 (original article).
IF (2014): 6.234
- 59#. Papamichalis P, Argyraki K, Papamichalis M, Loukopoulos A, Dalekos GN, **Rigopoulou EI**. Salmonella enteritidis Infection Complicated by Acute Myocarditis: A Case Report and Review of the Literature. **Cardiol Res Pract**. 2011;2011:574230. Epub 2011 May 23 (case report)
IF (2013): -
- 60#. Smyk D, Cholongitas E, Kriese S, **Rigopoulou EI**, Bogdanos DP. Primary biliary cirrhosis: family stories. **Autoimmune Dis**. 2011;2011:189585. (review)
IF (2014): -
61. Smyk DS, Bogdanos DP, Kriese S, Billinis C, Burroughs AK, **Rigopoulou EI**. Urinary tract infection as a risk factor for autoimmune liver disease: From bench to bedside. **Clin Res Hepatol Gastroenterol**. 2012; 36:110-21 (review)
IF (2014):1.638
62. Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, **Rigopoulou EI**. Reactivation of resolved hepatitis B virus infection after immunosuppression: Is it time to adopt pre-emptive therapy? **Clin Res Hepatol Gastroenterol**. 2012; 36:84-93 (original article)

IF (2014):1.638

63. Bogdanos DP, **Rigopoulou EI**, Smyk DS, Roggenbuck D, Reinhold D, Forbes A, Laass MW, Conrad K. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. **Autoimmun Rev.** 2011 Dec;11(2):143-8 (review)
IF (2014): 7.933
64. Mavropoulos A, Smyk D, **Rigopoulou EI**, Bogdanos DP. Human peripheral blood mononuclear cell culture for flow cytometric analysis of phosphorylated mitogen-activated protein kinases. **Methods Mol Biol.** 2012;806:275-85 (original article)
IF (2014): 1.29
65. Smyk DS, **Rigopoulou EI**, Lleo A, Abeles RD, Mavropoulos A, Billinis C, Invernizzi P, Bogdanos DP. Immunopathogenesis of primary biliary cirrhosis: an old wives' tale. **Immun Ageing.** 2011 Dec 2;8(1):12 (review)
IF* (2014): 3.538
66. Smyk DS, **Rigopoulou EI**, Muratori L, Burroughs AK, Bogdanos DP. Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. **Ann Hepatol.** 2012 Jan-Feb;11(1):7-14 (review)
IF (2014): 2.035
67. Bogdanos DP, Smyk DS, **Rigopoulou EI**, Mytilinaiou MG, Heneghan MA, Selmi C, Eric Gershwin M. Twin studies in autoimmune disease: Genetics, gender and environment. **J Autoimmun.** 2012; 38: J156-69 (review)
IF (2014): 8.410
- 68#. Rigamonti C, Bogdanos DP, Mytilinaiou MG, Smyk DS, **Rigopoulou EI**, Burroughs AK. Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. **Int J Rheumatol.** 2011;2011:976427. (review)
IF (2013): -
69. Mytilinaiou MG, Meyer W, Scheper T, **Rigopoulou EI**, Probst C, Koutsoumpas AL, Abeles D, Burroughs AK, Komorowski L, Vergani D, Bogdanos DP. Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis. **Clin Chim Acta.** 2012;413(15-16):1211-6.(original article)
IF (2014): 2.824
70. **Rigopoulou EI**, Roggenbuck D, Smyk DS, Liaskos C, Mytilinaiou MG, Feist E, Conrad K, Bogdanos DP. Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found. **Autoimmun Rev.** 2012;12:260-9 (review).
IF (2014): 7.933
- 71#. **Rigopoulou EI**, Smyk DS, Matthews CE, Billinis C, Burroughs AK, Lenzi M, Bogdanos DP. Epstein-barr virus as a trigger of autoimmune liver diseases.

- Adv Virol. 2012;2012:987471** (review)
IF (2014): -
72. Smyk S, **Rigopoulou EI**, Pares A, Billinis C, Burroughs AK, Muratori L, Invernizzi P, Bogdanos DP. Sex differences associated with primary biliary cirrhosis **Clin Dev Immunol 2012; 2012;2012:610504** (review).
IF (2014): 2.934
- 73#. Smyk DS, **Rigopoulou EI**, Koutsoumpas AL, Kriese S, Burroughs AK, Bogdanos DP. Autoantibodies in autoimmune pancreatitis. **Int J Rheumatol. 2012;2012:940831** (review)
IF (2014):-
74. Smyk D, **Rigopoulou EI**, Zen Y, Billinis C, Pares A, Bogdanos DP. Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis? **World J Gastroenterol 2012; 18(35): 4855-4865** (review)
IF (2014):2.369
75. Pavlidis P, Romanidou O, Roggenbuck D, Mytilinaiou MG, Al-Sulttan F, Liaskos C, Smyk DS, Koutsoumpas AL, **Rigopoulou EI**, Conrad K, Forbes A, Bogdanos DP. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease. **Clin Dev Immunol. 2012;2012:640835.** (original article)
IF (2014):2.934
76. Mavropoulos A, Orfanidou T, Liaskos C, Smyk DS, Billinis C, Blank M, **Rigopoulou EI**, Bogdanos DP. p38 mitogen-activated protein kinase (p38 MAPK)-mediated autoimmunity: lessons to learn from ANCA vasculitis and pemphigus vulgaris. **Autoimmun Rev. 2013 Mar;12(5):580-90.** (review)
IF (2014): 7.933
77. Bogdanos DP, Smyk DS, Invernizzi P, **Rigopoulou EI**, Blank M, Pouria S, Shoenfeld Y. Infectome: a platform to trace infectious triggers of autoimmunity. **Autoimmun Rev. 2013;12:726-40.** (review)
IF (2014):7.933
78. Bogdanos DP, Smyk DS, Invernizzi P, **Rigopoulou EI**, Blank M, Sakkas L, Pouria S, Shoenfeld Y. Tracing environmental markers of autoimmunity: introducing the infectome. **Immunol Res. 2013;56:220-40.** (review)
IF(2014):-
79. Liaskos C, Spyrou V, Roggenbuck D, Athanasiou LV, Orfanidou T, Mavropoulos A, Reinhold D, **Rigopoulou EI**, Amiridis GS, Billinis C, Bogdanos DP. Crohn's disease-specific pancreatic autoantibodies are specifically present in ruminants with paratuberculosis: implications for the pathogenesis of the human disease.

Autoimmunity. 2013;46:388- 94. (original article)

IF (2014): 2.714

80. Liaskos C, **Rigopoulou EI**, Orfanidou T, Bogdanos DP, Papandreou CN. CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases. **Clin Dev Immunol. 2013;2013:968041. (review)**
IF (2014): 2.934
- 81#. Mavropoulos A, Orfanidou T, Liaskos C, Smyk DS, Spyrou V, Sakkas LI, **Rigopoulou EI**, Bogdanos DP. p38 MAPK Signaling in Pemphigus: Implications for Skin Autoimmunity. *Autoimmune Dis. 2013;2013:728529. (review)*
IF (2014): -
82. Mavropoulos A, **Rigopoulou EI**, Liaskos C, Bogdanos DP, Sakkas LI. The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis. **Clin Dev Immunol. 2013;2013:569751 (review)**
IF (2014):2.934
- 83#. **Rigopoulou EI**, Zachou K, Gatselis NK, Papadamou G, Koukoulis GK, Dalekos GN. Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. **World J Hepatol. 2013;5:577-83. (original article)**
IF (2014):-
84. Kabaçam G, Wedemeyer H, Savaş B, Keskin O, Dalekos G, Tabak F, Idilman R, Erhardt A, Yalçın K, Bozdayi MA, Bozkaya H, Manns M, Dienes H, Yurdaydin C; HIDIT-1 Study Group. Collaborators: Berg T, Böcher W, Bohle H, Buggisch P, Cornberg M, Ersöz G, Feyerabend S, Hinrichsen H, Manok M, Häussinger D, Herzog W, Hofmann WP, Plein K, Hardt H, Porst H, Mederacke I, **Rigopoulou EI**, Sentürk H, v Wagner E. Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. **Liver Int. 2014;34:1207-15. (original article)**
IF (2014): 4.850
85. **Rigopoulou EI**, Zachou K, Gatselis N, Koukoulis GK, Dalekos GN. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. **Ann Hepatol. 2013 Jan-2014 Feb;13:127-35. (case report)**
IF (2014): 2.035
86. **Rigopoulou EI**, Bogdanos DP. Is primary biliary cirrhosis rare or common? The truth lies somewhere in between. **Liver Int. 2014;34:e165-7. (editorial)**
IF (2014): 4.850

87. Smyk DS, Koutsoumpas AL, Mytilinaiou MG, **Rigopoulou EI**, Sakkas LI, Bogdanos DP. Helicobacter pylori and autoimmune disease: cause Or bystander. **World J Gastroenterol.** **2014**;20(3):613-29. (review)
IF (2014):2.369
88. Mavropoulos A, Bogdanos DP, Liaskos C, Orfanidou T, Simopoulou T, Zafiriou E, Sakkas LI, **Rigopoulou EI**. Flow cytometric detection of p38 MAPK phosphorylation and intracellular cytokine expression in peripheral blood subpopulations from patients with autoimmune rheumatic diseases. **J Immunol Res.** **2014**;2014:671431. (original article)
IF (2014):2.934
89. Kaffe ET, **Rigopoulou EI**, Koukoulis GK, Dalekos GN, Moulas AN. Oxidative stress and antioxidant status in patients with autoimmune liver diseases. **Redox Rep.** **2015**;20:33-41. (original article)
IF (2014):1.522
90. Raszeja-Wyszomirska J, Wunsch E, Krawczyk M, **Rigopoulou EI**, Bogdanos D, Milkiewicz P. Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis. **Liver Int.** **2015**; 35:1764-71 (original article)
IF (2014):4.850
91. Liaskos C, Spyrou V, Athanasiou LV, Orfanidou T, Mavropoulos , **Rigopoulou EI**, Amiridis GS, Shoenfeld Y, Billinis C, Bogdanos DP. Crohn's disease-specific anti-CUZD1 pancreatic antibodies are absent in ruminants with paratuberculosis. **Clin Res Hepatol Gastroenterol.** **2015**;39(3):384-90 (original article)
IF (2014): 1.638
92. Bogdanos DP, Smyk DS, **Rigopoulou EI**, Sakkas LI, Shoenfeld Y. Infectomics and autoinfectomics: a tool to study infectious-induced autoimmunity. **Lupus.** **2015**; 24(4-5):364-73. (review)
IF (2014): 2.197

Chapters in books:

1. Dimitrios.P. Bogdanos, Cristina Rigamonti, Daniel Smyk, Maria G. Mytilinaiou, **Eirini I. Rigopoulou** and Andrew K. Burroughs. Emerging issues in the Immunopathogenesis, Diagnosis, and Clinical Management of Primary Biliary Cirrhosis associated Systemic Sclerosis. In: Systemic Sclerosis- An update on

the aberrant immune system and clinical features. Timothy Radstake (Eds.) *Intech*; page 151-166.

2. **El Rigopoulou**, D. Smyk, T. Orfanidou, DP.Bogdanos, ME. Gershwin. Bacterial infection in Liver. In: *Liver Immunology: Principles and Practice*. ME Gershwin, LM Vierling and MP Manns (Eds.), Springer; page 123-144.
3. DS.Smyk, **El. Rigopoulou**, P. Invernizzi, DP.Bogdanos. Infection and Autoimmune Liver Diseases. In: *Infections and Autoimmunity*. Y. Shoenfeld, N. Agmon-Levin, NR Rose (Eds.) Elsevier; 2015, page 839-858

PEER REVIEWED PAPERS PUBLISHED IN THE FORM OF ABSTRACTS

1. Kostopanagioutou G., Theodoraki K., Pysopoulos N., **Rigopoulou E.**, Dafnios N., Prachalias A., Smirniotis V., Tsantoulas D., Papadimitriou I. Hemodynamic changes in anhepatic versus ischemic acute liver failure Experimental model. *Hepatology* 1997; 26 (4): Supplement 166 A
2. Demonakou M., **Rigopoulou E.**, Pysopoulos N., Kontogianni A., Tamvakis N., Hatzakis A., Tsantoulas D. Liver histology and viral load in anti- HCV positive individuals with normal or abnormal ALT levels. *Hepatology* 1997; 26 (4): Supplement 498 A
3. **Rigopoulou E.**, Pysopoulos N, Bamias G, Demertzi E, Moutsopoulou A, Tsagaris M, Papafragas V, Tsantoulas D. Thyroid abnormalities before and during treatment in patients with chronic hepatitis B and C. *J Hepatol* 1998; 28(1): Supplement 192
4. Pysopoulos N, Smirniotis V, Kostopanagioutou G, Papalois A, Hondroudaki I, **Rigopoulou E.**, Elefteriou A, Tsantoulas D, Papadimitriou I. Laparoscopic hepatectomy in swine. Hemodynamic and biochemical alterations (experimental study). *J Hepatol* 1998; 28(1): Supplement 154
5. Lau KK G., Chokshi S., Kwok A., Hawkins B., **Rigopoulou E.**, Williams R., Naoumov VN. Dysfunction of dendritic cells in chinese patients with chronic HBV infection: a study of HLA identical siblings. *Hepatology* 1999; 30(4): Supplement 440 A
6. **Rigopoulou E.I.**, Abbott W GH, Williams R, Lau JYN, Naoumov NV. Blocking of IL-10 Receptor - a novel approach to stimulate virus-specific T cell reactivity in chronic hepatitis C virus (HCV) infection. *Hepatology* 2000; 32 (4), Supplement 304A
7. **Rigopoulou E.I.**, Abbott W GH, Williams R, Lau JYN, Naoumov NV. Direct evidence for the immunomodulatory action of Ribavirin on T-cell reactivity to hepatitis C virus (HCV). *Hepatology* 2000; 32 (4), Supplement 374A
8. Naoumov NV, Suri D, **Rigopoulou EI**, Machell T, Mullerova I, Chokshi S, Rice S, Tedder S, Williams R. Combination treatment with lamivudine plus interleukin-12 shows greater antiviral activity in chronic hepatitis B. *Hepatology* 2000; 32 (4), Supplement 376A
9. Vyas P. Schilling R, **Rigopoulou E.I.**, Williams R, Naoumov NV. Characterization of the cellular and humoral immune responses to TT virus

- (TTV) in healthy subjects and patients with liver diseases. *Hepatology* 2000; 32 (4), Supplement 381A
10. Lau GKK, Chokshi S, Hawkins B, **Rigopoulou E**, Williams R, Naoumov NV. Role of dendritic cells in HBV viral persistence in Chinese patients. *Journal of Gastroenterology and Hepatology* 2000; 15 (Suppl): B124
 11. I. Mullerova, **E.I. Rigopoulou**, P Haigh, H. Cooksley, R Williams, N.V. Naoumov. Contrasting functional characteristics of intrahepatic HCV-specific CD4+ and CD8+ T lymphocytes in mild and severe chronic hepatitis C. *J Hepatol* 2001; 34 (1), Supplement, 25 (1221)
 12. D.P. Bogdanos, M. Lenzi, M. Okamoto, Yun Ma, U.C. Sharma, **E. Rigopoulou**, L. Muratori, R. Williams, D. Tsantoulas, F.B. Bianchi, D. Vergani. Cross-reactive immunity between viral mimics and cytochrome P4502D6254-271, the immunodominant epitope of LKM-1 autoantibody is associated with a specific immunogenetic background. *J Hepatol* 2001; 34 (1), Supplement, 120 (683)
 13. I Mullerova, **E. Rigopoulou**, P. Haigh, H. Cooksley, M. Lucas, P. Klenerman, D. Mesogiti, J. Jenkins, R. Williams, N.V. Naoumov. Quantitative and qualitative changes in HCV-specific liver infiltrating T- cells parallel the progression of liver damage in chronic hepatitis C. *Hepatology* 2001; 34 (4): Supplement 430A
 14. W.G.H. Abbott, **E. Rigopoulou**, P. Haigh, I. Mullerova, M. Novelli, A. Winstanley, R. Williams, N.V. Naoumov. Genetic differences in interleukin 10 production do not influence the severity of chronic hepatitis C. *Hepatology* 2001; 34 (4): Supplement 434A
 15. **E.I. Rigopoulou**, E.T. Davies, D.P. Bogdanos, G. Koukoulis, G.N. Dalekos, D. Vergani. Primary biliary cirrhosis (PBC) specific antinuclear antibodies (ANA) have prognostic value and a distinct immunoglobulin isotype. *J Hepatol* 2004; 40 (1): Supplement 552A
 16. S.P. Georgiadou, K. Zachou, **E. Rigopoulou**, C. Liaskos, P. Mina, F. Gerovasilis, E. Makri, G.N. Dalekos. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse non-viral hepatic diseases. *J Hepatol* 2004; 40 (1): Supplement 526A
 17. DP Bogdanos, S. Leoni, H. Baum, M. Okamoto, P. Montalto, U.C. Sharma, **E.I. Rigopoulou**. J. Vlachogiannakos, Y. Ma, A.K. Burroughs, D. Vergani. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its lactobacillus mimic. *J Hepatol* 2004; 42 (2): Supplement 634A
 18. A. Tsirikoni, D.S. Kyriakou, **E.I. Rigopoulou**, M.G. Alexandrakis, K. Zachou, F. Passam, G.N. Dalekos. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and Primary biliary cirrhosis. *J Hepatol* 2005; 42 (2): Supplement 656A
 19. C. Liaskos, T.A. Zografos, E. Togousidis, K. Zachou, N. Gatselis, **E. Rigopoulou**, A. Germenis, G.N. Dalekos. Alterations of leptin levels during IFN- α treatment in patients with chronic viral hepatitis B and C: Evidence of an IFN- α mediated suppression of leptin production. *Hepatology* 2005; 42 (4), Supplement 1209A
 20. C. Liaskos, D.P. Bogdanos, **E. Rigopoulou**, G. Mieli-Vergani, G.N. Dalekos, D. Vergani. Identification of a novel nuclear target-antigen in hepatitis C and B virus chronic infections. *J Hepatol* 2006; 44 (2): Supplement 433A
 21. C. Liaskos, D.P. Bogdanos, G. Norman, **E.I. Rigopoulou**, D. Vergani, G.N. Dalekos. Detection of a new autoantibody in patients with chronic HCV infection. *J Hepatol* 2006; 44 (2): Supplement 434A

22. **E.I. Rigopoulou**, E.T. Davies, D.P. Bogdanos, C. Liaskos, G. Koukoulis, D. Vergani. Immunoglobulin G3 subclass antimitochondrial antibodies are associated with a more severe disease course in primary biliary cirrhosis. *Hepatology* 2006; 44 (4), Supplement 1186A
23. P. Papamichalis, K. Zachou, A. Veloni, E.K. Karacosta, L. Kypri, I. Mamaloudis, **E.I. Rigopoulou**, G.N. Dalekos. The revised score of the international autoimmune hepatitis group (AIHG) in diverse liver diseases including autoimmune hepatitis, (AIH), overlapping with other liver disorders. *Hepatology* 2006; 42 (4), Supplement 1208A
24. C. Liaskos, D.P. Bogdanos, **E.I. Rigopoulou**, A. Garagounis, T. Zografos, E.T. Davies, G.N. Dalekos. Diagnostic significance of anti-filamentous actin (f-actin) antibodies in autoimmune hepatitis. *Hepatology* 2006; 44 (4), Supplement 1214A
28. **E.I. Rigopoulou**, E.T. Davies, D.P. Bogdanos, C. Liaskos, G. Koukoulis, G.N. Dalekos, D. Vergani. Clinical significance of immunoglobulin G subclass anti-mitochondrial antibodies in Primary Biliary Cirrhosis. *Autoimmunity Reviews*. Abstracts of the 5th International Congress on Autoimmunity, Sorrento Italy, 29 November-3, p. 183
26. D.P. Bogdanos, C. Liaskos, G.L. Norman, M. Horner, D. Murphy, N. Gatselis, **E.I. Rigopoulou**, H. Smith, D. Vergani, G.N. Dalekos. Interferon-alpha unmasks a novel golgi-like immunofluorescence pattern specifically present in patients with chronic hepatitis C virus (HCV) infection. *Autoimmunity Reviews*. Abstracts of the 5th International Congress on Autoimmunity, Sorrento Italy, 29 November-3 December 2006, p. 257-8
29. C. Liaskos, G.L. Norman, P. Papamichalis, A. Garagounis, Z. Shums, **E.I. Rigopoulou**, D.P. Bogdanos, G.N. Dalekos. A new ELISA simultaneously detects Primary Biliary Cirrhosis-specific mitochondrial and nuclear autoantibodies. *Autoimmunity Reviews*. Abstracts of the 5th International Congress on Autoimmunity, Sorrento Italy, 29 November-3 December 2006, p. 270
28. C. Liaskos, D.P. Bogdanos, N. Gatselis, M. Homer, Z. Shums, D. Murphy, **E.I. Rigopoulou**, H. Smith, D. Vergani, G.L. Norman, G.N. Dalekos. Chronic hepatitis C is characterised by an interferon-alpha induced novel autoantibody giving a crescent pattern by indirect immunofluorescence. *J Hepatol* 2007; 46 (Suppl 1): 172
29. T. Zografos, C. Liaskos, **E.I. Rigopoulou**, E. Togousidis, K. Makaritsis, A. Germanis, G.N. Dalekos. Adiponectin: a new independent predictor of liver steatosis and response to IFN- α treatment in chronic hepatitis C?. *Hepatology* 2007; 46 (4), Supplement 449A
30. S. Gabeta, G.L. Norman, N. Gatselis, C. Liaskos, P.A. Papamichalis, A. Garagounis, K. Zachou, **E.I. Rigopoulou**, G.N. Dalekos. IgA isotype specific anti-b2dpi antibodies in patients with autoimmune liver diseases. *J Hepatol* 2008; 48 (Suppl 2):330.
1. M. Mytilinaiou, E.S. Spyrou, A. Koutsoumpas, **E.I. Rigopoulou**, G.N. Dalekos, D. Vergani, D.P. Bogdanos. Investigation of molecular mimicry and immunological cross-reactivity as mechanism responsible for the presence of anti-Ro52 antibodies in primary biliary cirrhosis. *Hepatology* 2008; 48: Supplement 612A
2. P. Pavlidis, M. Mytilinaiou, A. Koutsoumpas, **E.I. Rigopoulou**, D. Vergani, D.P. Bogdanos. The role of herpes simplex virus type 1 in the induction of

- promyelocytic leukemia specific responses in primary biliary responses. *Hepatology* 2009; 50 (4): Supplement 1005A
3. M. Mytilinaïou, A. Pares, ES. Spyrou, **E.I. Rigopoulou**, GN. Dalekos, D. Vergani, DP. Bogdanos. Diagnostic and clinical significance of anti-Ro52 antibodies in 609 samples with primary biliary cirrhosis from UK, Spain and Greece. *Hepatology* 2009; 50 (4): Supplement 1002 A
 4. M. Mytilinaïou, L. Komorowski, **E.I. Rigopoulou**, A. Janssen, C. Probst, D. Vergani, DP. Bogdanos. F1F0-atpase as an autoantigenic target in patients with anti-mitochondrial antibody negative primary biliary cirrhosis. *Hepatology* 2010; 52(4): Supplement 493A.
 5. K. Zachou, N. Gatselis, G. Papadamou, **E.I. Rigopoulou**, G.N. Dalekos. Mycophenolate for Autoimmune Hepatitis treatment: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. *European J Intern Med* 2011: 22 (Suppl 1):S24
 37. Hepatocellular carcinoma: Clinical characteristics of the disease in Central Greece. Eriola Koumati, Aggelos Stefos, Kalliopi Zachou, Georgia Papadamou, **Eirini I. Rigopoulou**, George N. Dalekos. *European J Intern Med* 2011: 22 (Suppl 1):S50
 6. Epidemiological characteristics and burden of alcoholic liver disease in Central Greece. Aggelos Stefos, Kalliopi Zachou, Georgia Papadamou, **Eirini I. Rigopoulou**, George N. Dalekos. *European J Intern Med* 2011: 22 (Suppl 1):S89
 31. K. Zachou, N. Gatselis, G. Papadamou, **E.I. Rigopoulou**, G.N. Dalekos. Mycophenolate for Autoimmune Hepatitis treatment: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. *European J Intern Med* 2011: 22 (Suppl 1):S24
 36. E. Koumati, A. Stefos, K. Zachou, G. Papadamou, **E.I. Rigopoulou**, GN. Dalekos. Hepatocellular carcinoma: Clinical characteristics of the disease in Central Greece. *European J Intern Med* 2011: 22 (Suppl 1):S50
 37. A. Stefos, K. Zachou, G. Papadamou, **E.I. Rigopoulou**, GN. Dalekos. Epidemiological characteristics and burden of alcoholic liver disease in Central Greece.. *European J Intern Med* 2011: 22 (Suppl 1):S89.
 38. C. Liaskos, M. Mytilinaïou, A. Grammatikopoulos, D. Smyk, T. Orfanidou, A. Mavropoulos, G. Norman, **E.I. Rigopoulou**, G. Mieli-Vergani, D.P. Bogdanos, D. Vergani. New sensitive technique for the detection of anti-smooth muscle antibodies in autoimmune hepatitis. *Hepatology* 2013: 56 (Suppl 1): 171A
 39. A. Mavropoulos, **E.I. Rigopoulou**, D. Vergani and D.P Bogdanos. Flow cytometric analysis of p38 MAPK phosphorylation in peripheral CD56+ subsets- Relevance to immune mediated liver pathology. *J Hepatol* 2012
 40. K. Zachou, N.K. Gatselis, S. Gabeta, A.I. Saitis, G. Papadamou, **E.I. Rigopoulou**, G.N. Dalekos. Autoimmune hepatitis natural history: a single Greek center experience focused on long-term effect of mycophenolate mofetil as first line treatment. *Hepatology* 2013; 58 (Suppl1): 568A
 41. E. Spyrou, L. Komorowski, C. Probst, **E.I. Rigopoulou**, DP. Bogdanos, GN. Dalekos. Longitudinal determination of IgA isotype-specific antibodies targeting the major recombinant mitochondrial antigens in patients with primary biliary cirrhosis. *Hepatology* 2013; 58 (Suppl 1)

42. A. Mavropoulos, T. Simopoulou, C. Liaskos, E. Georgiou, C. Katsiari, **E.I. Rigopoulou**, D.P Bogdanos and L.I Sakkas. CD56+CD7+CD11c+ (NK/DC) cell imbalance in patients with autoimmune rheumatic diseases. J Autoimmunity 2014
43. Athanasios Mavropoulos, C. Liaskos, L.I Sakkas, D.P Bogdanos and **E.I. Rigopoulou**. Phospho-p38 MAPK positive CD56+ subsets expressing IL-10 in autoimmune rheumatic diseases. J Autoimmunity 2014
44. C. Liaskos, A. Vrana, T. Simopoulou, A. Mavropoulos, M. Mytilinaiou, **E.I. Rigopoulou**, D.P Bogdanos and L.I Sakkas. Is there any role for *Helicobacter Pylori* in the pathogenesis of systemic sclerosis. J Autoimmunity 2014

CITATIONS

Citations up to 20-6-2015 (source: Scopus)

Total number of citations (scopus):1984, self-citations: 294

Total number of citations (google scholar): 2805

Total impact factor: 464.023

Personal impact factor: 212.5

Total impact factor in original articles: 312.39

Personal impact factor in original articles: 134.7

h-index (Scopus)= 25

Average citations per year since 2002=142

Average citation number in all publications: 21.5 citations/ publication

Average citation number in original articles: 31.3 citations/ original article

Table with best 10 citations:

Publication	Author	Year	vol:	page
No 25				
Tsironi E et al	Lancet (IF= 45.217)	2006;	368:	1936
No 55				
Hughes S et al	Lancet (IF= 45.217)	2011;	378:	73
No 18				

Brooks DG et al	Nat Med (IF= 27.363)	2006;	12:	1301
Tinoco R et al	Immunity (IF= 21.561)	2009;	31:	145
Harker JA et al	Immunity (IF= 21.561)	2013	39:	548
Wilson EB et al	Science (IF= 33.611)	2013	340:	202

No 3

Wusthorn K	Gut (IF= 14.66)	2010;	59:	1430
------------	-------------------------	-------	-----	------

No 5

Czaja AJ et al	Gastroenterology (IF= 16.716)	2010;	139:	58
----------------	-------------------------------------------------------	-------	------	----

No 22

Reherman B et al	J Hepatology (IF= 11.336)	2007;	46:	508
Wu J et al	Gastroenterology (IF= 16.716)	2010;	138:	165
Michel M-L et al	J Hepatology (IF= 11.336)	2011;	54:	1286

GRANTS – FINANCIAL SUPPORT

1. **Helenc Center for the Control of Infections (KEELPNO)** (1/1/2004-30/9/2004) - **8.804€** «Specialised services for the confirmation of HCV infection- an epidemiological survey»
2. **Alexander S. Onassis Public Benefit Foundation** (1/10/2006-30/9/2008) **24.200€** «Study of HBV specific immuno responses in patients with occult HBV infection alone or in the presence of other liver diseases»
3. **E-rare consortium EPINOSTICS**. “Autoimmune liver diseases“. Epitope peptide mapping – The entry to novel and innovative diagnostic and therapeutic applications. (January 2008, duration 36 months). Project co-ordinator: Professor Hans-Jurgen Thiessen (Rostock Germany)
4. **Herakleitos General Secretariat for Research & Technology (GSRT), Hellenic Ministry of Development** 2010-2013 (Starting June 2011)- **45.000€**- Support for the research of Dr M Bakarozzi
5. **Herakleitos GSRT, Hellenic Ministry of Development** 2010-2013 (Starting June 2011)- **45.000€**- Support for the research of Dr A Koutsoumpas).
6. **Innovation ticket (7.000€)**- Development of an enzyme linked immunoassay for the detection of IgG subclasses of autoantibodies. Funding body: (General Secretariat for Research and Education).

REVIEWER IN PEER REVIEW JOURNALS

Journal of Antimicrobial Chemotherapy
Autoimmunity
QJM
World J Hepatology
BMC Gastroenterology
Archives of Medical Science
Liver International
Annals of Gastroenterology
Biomed Research International
Expert Review of Gastroenterology and Hepatology
Clinical Developmental Immunology
Journal of Immunologic Research
Immuno-Gastroenterology
Transplantation Infectious Diseases
BMC Infectious Diseases

Reviewer for grant giving bodies

Research Fund Secretariat, Food and Health Bureau, The Government of the Hong Kong Special Administrative region.

MEMBER OF SOCIETIES

1. Hellenic Association for the Study of the Liver
2. Society of Internal Medicine of North Greece
3. European Association for the Study of the Liver

ADMINISTRATIVE WORK

1. Member of the General Assembly of the Department of Medicine, University of Thessaly twice since 2003.
2. In September 2008, I was appointed as supervisor of 1 out of 3 medical teams of the Department of Internal Medicine, consisting of 1 chief resident (registrar), four senior house officers and 2 consultants with whom "post take" rounds are undertaken in general medical in-patients. These also function as post-graduate training sessions.
3. Deputy member of the Examination Committee based in Larissa, Thessaly up to 31/12/2011, which is responsible for the final written and oral examination for the accreditation of the speciality of Internal Medicine (Ministry of Health and Social Welfare- decision number Y7α/Γ.Π. οικ. 70469, 12/6/2010).
4. Co-ordinator of the 'Support and Management of Chronic Alcohol Abusers' Out-patient clinic of the University General Hospital of Larissa from 29/7/2010 (together with Assistant Professor of Psychiatry O. Mouzas)

decision number (20/29/7/2010 (E.H.Δ.64°)).

5. Deputy member of the Examination Committee based in Larissa, Thessaly up to 31/12/2015, which is responsible for the final written and oral examination for the accreditation of the speciality of Internal Medicine (Ministry of Health and Social Welfare- decision number Y7α/Γ.Π. οικ. 18286, 24/2/2014).

MEMBER OF ORGANIZING COMMITTEES OF CONGRESSES/ CONFERENCES/SYMPOSIA

1. 1st Mediterranean Summer School, 21-24 September 1998
2. 5th Mediterranean Medical Congress, 25-27 September 1998
3. Postgraduate meeting in liver diseases, Athens, 23 March 2002
4. Internal Medicine Days Central Greece, 19-21 March 2009
5. Panhellenic Congress of Thalassaemias, 15-17 May 2009
6. Autumn days in Internal Medicine, Old Panteleimon, 25-26 September 2009
7. Participation in the scientific committee of 5th Educational congress of the Hellenic Foundation of Gastroenterology and Nutrition with the title: "Progress in Gastroenterology and Hepatology", Athens, 5-6 March 2010
8. 2nd Congress of Internal Medicine- Central Greece, 18-20 March 2010
9. Autumn days in Internal Medicine, Portalia Pilio, 1-2 October 2010
10. 3rd Congress of Internal Medicine- Central Greece, 10-12 March 2011
11. Scientific committee of the 6th International Congress of Internal Medicine of Central Greece, Larissa, 27-29 March 2014
12. Scientific committee of the 10th Educational congress of the Hellenic Foundation of Gastroenterology and Nutrition with the title: "Progress in Gastroenterology and Hepatology", Athens, 7-8 March 2015
13. Scientific committee of the 7th International Congress of Internal Medicine of Central Greece, Larissa 27-29 March 2015

INVITATED SPEAKER

I have participated as Invited speaker in over 40 congresses or seminars in Greece.

PRESENTATIONS IN INTERNATIONAL MEETINGS

1. **Rigopoulou E.**, Pyrsopoulos N, Demonakou M, Bamias G, Hatzakis A., Tsantoulas D. Early treatment of chronic hepatitis C with Interferon - a.
4th Mediterranean Medical congress. Limassol, Cyprus, 13- 17 November 1996
2. Pyrsopoulos N., **Rigopoulou E.**, Bamias G., Legakis N., Daikos G. Epidemiology of HCV infection in Greece.
4th Mediterranean Medical Congress, Limassol, Cyprus 13-17 November 1996
3. Kostopanagiotou G., Theodoraki K., Pyrsopoulos N., **Rigopoulou E.**, Dafnios N., Prachalias A., Smirniotis V., Tsantoulas D., Papadimitriou I. Hemodynamic changes in anhepatic versus ischemic acute liver failure. Experimental model.

- American Association for the Study of Liver Diseases (AASLD), 7-11 November 1997*
4. G.Kostopanagiotou, K. Theodoraki, N. Pyrsopoulos, **E. Rigopoulou**, N.Dafnios, A. Prachalias, V.Smirniotis, D.Tsantoulas, J. Papadimitriou. Hemodynamic changes in anhepatic versus ischemic acute liver failure. Experimental model. *20th European Federation Congress (International College of Surgeons), 17- 20 September 1997*
 5. N.Pyrsopoulos, **E. Rigopoulou**, A. Moutsopoulou, I. Varsami, V. Papafragas, D. Tsantoulas Does antiviral treatment trigger autoimmunity in patients with chronic hepatitis C?. *5th Mediterranean Medical Congress. Samos, Greece 25-27 September 1998*
 6. **E. Rigopoulou**, N. Pyrsopoulos, G. Bamias, A.Moutsopoulou, I.Varsami, V. Papafragas, D. Tsantoulas. Thyroid abnormalities in patients with chronic viral hepatitis. Influence of treatment with IFN-a or combination with ribavirin. *5th Mediterranean Medical Congress. Samos, Greece 25-27 September 1998*
 7. N. Pyrsopoulos, K. Pythara, M. Tsagaris, A. Karabekiou, **E.Rigopoulou**, M. Hatzopoulou, F. Ioakim, N.Trakas, F. Lissiotis. G. Malahias, D. Tsantoulas. Percutaneous needle liver biopsy. Is it a safe procedure? *5th Mediterranean Medical Congress. Samos, Greece, 25-27 September 1998 (*
 8. Lau KK G., Chokshi S., Kwok A., Hawkins B., **Rigopoulou E.**, Williams R., Naoumov VN. Dysfunction of dendritic cells in chinese patients with chronic HBV infection: a study of HLA identical siblings. *British Association for the Study of the Liver (BASL), London, September 1999 και 50th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Dallas 5-9 November 1999*
 9. Evans P., Smith S., Hirschfield G., **Rigopoulou E.**, Wreghitt GT.,Wight D.,Taylor JC., Alexander JM G. Recipient HLA-DR3, Tumor Necrosis Factor promoter allele-2 and cytomegalovirus infection are inter-related risk factors for chronic rejection of liver grafts. *British Association for the Study of the Liver (BASL), London, September 1999*
 - 10.Lau KK G., Suri D., Liang R., **Rigopoulou E.**, Chokshi S., Thomas MG., Willimas R., Naoumov VN. Adoptive transfer of HbcAg- specific CD4+T cells is associated with HbsAg clearance in chinese chronic HBV carriers. *50th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Dallas 5-9 November 1999*
 - 11.**Rigopoulou E.I.**, Abbott WGH, Williams R, Lau JYN, Naoumov NV. Blocking of IL-10 Receptor - a novel approach to stimulate virus-specific T cell reactivity in chronic hepatitis C virus (HCV) infection. *British Association for the Study of the Liver (BASL), Southampton, UK September 2000 and 51st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Dallas 27-31 October 2000*
 - 12.**Rigopoulou E.I.**, Abbott W GH, Williams R, Lau JYN, Naoumov NV. Direct evidence for the immunomodulatory action of Ribavirin on T-cell reactivity to hepatitis C virus (HCV). *British Association for the Study of the Liver (BASL), Southampton, UK September 2000 and 51st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Dallas 27-31 October 2000* Naoumov NV,
 13. Suri D, **Rigopoulou EI**, Machell T, Mullerova I, Chokshi S, Rice S, Tedder S, Willimas R. Combination treatment with lamivudine plus interleukin-12 shows greater antiviral activity in chronic hepatitis B.

- British Association for the Study of the Liver (BASL), Southampton, UK September 2000 and 51st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Dallas 27-31 October 2000*
14. Vyas P., Schilling R, **Rigopoulou E.I.**, Williams R, Naoumov NV. Characterization of the cellular and humoral immune responses to TT virus (TTV) in healthy subjects and patients with liver diseases.
British Association for the Study of the Liver (BASL), Southampton, UK September 2000 και 51st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Dallas 27-31 October 2000
 15. I. Mullerova, **E.I. Rigopoulou**, P Haigh, H. Cooksley, R Williams, N.V. Naoumov. Contrasting functional characteristics of intrahepatic HCV-specific CD4+ and CD8+ T lymphocytes in mild and severe chronic hepatitis C.
36^o Annual Meeting of the European Association of the Study of the Liver (EASL), PRAGUE 18-22 April 2001
 16. D.P. Bogdanos, M. Lenzi, M. Okamoto, Yun Ma, U.C. Sharma, **E. Rigopoulou**, L. Muratori, R. Williams, D. Tsantoulas, F.B. Bianchi, D. Vergani. Cross-reactive immunity between viral mimics and cytochrome P450D6₂₅₄₋₂₇₁, the immunodominant epitope of LKM-1 autoantibody is associated with a specific immunogenetic background.
36^o Annual Meeting of the European Association of the Study of the Liver (EASL), Prague 18-22 April 2001
 17. Lau G.K.K., Suri D., **Rigopoulou E.I.**, Chokshi S., Kwok A, Williams R., Naoumov NV. Dendritic cell dysfunction and with low interleukin-12 (IL-12) production determine the weak T-lymphocyte reactivity in chronic hepatitis B virus (HBV) infection.
Congress of the Association of Physicians of Great Britain, Edinburgh 2001.
 18. I Mullerova, **E. Rigopoulou**, P. Haigh, H. Cooksley, M. Lucas, P. Klenerman, D. Mesogiti, J. Jenkins, R. Williams, N.V. Naoumov. Quantitative and qualitative changes in HCV-specific liver infiltrating T- cells parallel the progression of liver damage in chronic hepatitis C.
British Association for the Study of the Liver (BASL), London, UK September 2001 and 52nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Dallas 27-31 November 2001
 19. W.G.H. Abbott, **E. Rigopoulou**, P. Haigh, I. Mullerova, M. Novelli, A. Winstanley, R. Williams, N.V. Naoumov. Genetic differences in interleukin 10 production do not influence the severity of chronic hepatitis C.
British Association for the Study of the Liver (BASL), London, UK September 2001 και 52nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Dallas 27-31 November 2001
 20. **E.I. Rigopoulou**, E.T. Davies, C. Liaskos, K. Zachou, D.P. Bogdanos, G.N. Dalekos, D. Vergani. Prevalence and clinical significance of disease specific antinuclear antibodies in Greek patients with primary biliary cirrhosis. *Falk Symposium No 136. Cholestatic Liver Disease: Therapeutical options and perspectives. 15-16 October 2003, Freiburg, Germany*
 21. **E.I. Rigopoulou**, E.T. Davies, D.P. Bogdanos, G. Koukoulis, G.N. Dalekos, D. Vergani. Primary biliary cirrhosis (PBC) specific antinuclear antibodies (ANA) have prognostic value and a distinct immunoglobulin isotype.
39^o Annual Meeting of the European Association of the Study of the Liver (EASL), Berlin, 14-18 Απριλίου 2004

22. S.P.Georgiadou, K. Zachou, **E. Rigopoulou**, C. Liaskos, P. Mina, F. Gerovasilis, E. Makri, G.N. Dalekos. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse non-viral hepatic diseases.
39^o Annual Meeting of the European Association of the Study of the Liver (EASL), Berlin, 14-18 Απριλίου 2004
23. K. Zachou, **E. Rigopoulou**, A. Tsikrikoni, M.G. Alexandrakis, F. Passam, D.S. Kyriakou, N. E. Stathakis, G.N. Dalekos. Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production.
Falk Symposium No 142. Autoimmune Liver Disease. 13-14 October 2004, Freiburg, Germany
24. C. Liaskos, K. Zachou, **E. Rigopoulou**, S. Georgiadou, N. Gatselis, G.N. Dalekos. Prevalence and clinical significance of anticardiolipin antibodies (anti-CLAbs) in patients with autoimmune hepatitis (AIH).
Falk Symposium No 142. Autoimmune Liver Disease. 13-14 October 2004, Freiburg, Germany
25. DP Bogdanos, S. Leoni, H. Baum, M. Okamoto, P. Montalto, U.C. Shirma, **E.I. Rigopoulou**, J. Vlachogiannakos, Y. Ma, A.K. Burroughs, D. Vergani. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its lactobacillus mimic.
40th Annual Meeting of the European Association of the Study of the Liver (EASL), Paris, 13-17 Απριλίου 2005
26. A. Tsikrikoni, D.S. Kyriakou, **E.I. Rigopoulou**, M.G. Alexandrakis, K. Zachou, F. Passam, G.N. Dalekos. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and Primary biliary cirrhosis.
40th Annual Meeting of the European Association of the Study of the Liver (EASL), Paris, 13-17 Απριλίου 2005
27. C. Liaskos, T.A. Zografos, E. Togousidis, K. Zachou, N. Gatselis, **E. Rigopoulou**, A. Germenis, G.N. Dalekos. Alterations of leptin levels during IFN- α treatment in patients with chronic viral hepatitis B and C: Evidence of an IFN- α mediated suppression of leptin production.
56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco 11-15 November 2005
28. C. Liaskos, D.P. Bogdanos, **E. Rigopoulou**, G. Mieli-Vergani, G.N. Dalekos. D. Vergani. Identification of a novel nuclear target-antigen in hepatitis C and B virus chronic infections.
41st Annual Meeting of the European Association of the Study of the Liver (EASL), Vienna, 26-30 Απριλίου 2006
29. C. Liaskos, D.P. Bogdanos, G. Norman, **E.I. Rigopoulou**, d. Vergani, G.N. Dalekos. Detection of a new autoantibody in patients with chronic HCV infection.
41st Annual Meeting of the European Association of the Study of the Liver (EASL), Vienna, 26-30 Απριλίου 2006
30. **E.I. Rigopoulou**, E.T. Davies, D.P. Bogdanos. C. Liaskos. G. Koukoulis, D. Vergani. Immunoglobulin G3 subclass antimitochondrial antibodies are associated with a more severe disease course in primary biliary cirrhosis.
57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, 27-31 November 2006

31. P. Papamichalis, K. Zchou, A. Veloni, E.K. Karacosta, L. Kypri, I. Mamaloudis, **E.I. Rigopoulou**, G.N. Dalekos. The revised score of the international autoimmune hepatitis group (AIHG) in diverse liver diseases including autoimmune hepatitis, (AIH), overlapping with other liver disorders.
57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, 27-31 November 2006
32. C. Liaskos, D.P. Bogdanos, **E.I. Rigopoulou**, A. Garagounis, T. Zografos, E.T. Davies, G.N. Dalekos. Diagnostic significance of anti-filamentous actin (f-actin) antibodies in autoimmune hepatitis.
57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, 27-31 November 2006
33. **E.I. Rigopoulou**, E.T. Davies, D.P. Bogdanos, C. Liaskos, G. Koukoulis, G.N. Dalekos, D. Vergani. Clinical significance of immunoglobulin G subclass anti-mitochondrial antibodies in Primary Biliary Cirrhosis.
5th International Congress on Autoimmunity, Sorrento Italy, 29 November-3 December 2006
34. D.P. Bogdanos, C. Liaskos, G.L. Norman, M. Horner, D. Murphy, N. Gatselis, **E.I. Rigopoulou**, H. Smith, D. Vergani, G.N. Dalekos. Interferon-alpha unmasks a novel golgi-like immunofluorescence pattern specifically present in patients with chronic hepatitis C virus (HCV) infection
5th International Congress on Autoimmunity, Sorrento Italy, 29 November-3 December 2006
35. C. Liaskos, G.L. Norman, P. Papamichalis, A. Garagounis, Z. Shums, **E.I. Rigopoulou**, D.P. Bogdanos, G.N. Dalekos. A new ELISA simultaneously detects Primary Biliary Cirrhosis-specific mitochondrial and nuclear autoantibodies.
5th International Congress on Autoimmunity, Sorrento Italy, 29 November-3 December 2006
36. C. Liaskos, D.P. Bogdanos, N. Gatselis, M. Homer, Z. Shums, D. Murphy, **E.I. Rigopoulou**, H. Smith, D. Vergani, G.L. Norman, G.N. Dalekos. Chronic hepatitis C is characterised by an interferon-alpha induced novel autoantibody giving a crescent pattern by indirect immunofluorescence.
42nd Annual Meeting of the European Association of the Study of the Liver (EASL), Barcelona, 11-15 Απριλίου 2007
37. T. Zografos, C. Liaskos, **E.I. Rigopoulou**, E. Togousidis, K. Makaritsis, A. Germentis, G.N. Dalekos. Adiponectin: a new independent predictor of liver steatosis and response to IFN-α treatment in chronic hepatitis C?
58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, 1-6 November 2007
38. S. Gabeta, G.L. Norman, N. Gatselis, C. Liaskos, P.A. Papamichalis, A. Garagounis, K. Zachou, **E.I. Rigopoulou**, G.N. Dalekos. IgA isotype specific anti-b2dpi antibodies in patients with autoimmune liver diseases.
43rd Annual Meeting of the European Association of the Study of the Liver (EASL), Milan, Απριλίου 2008
39. M. Mytilinaïou, E.S. Spyrou, A. Koutsoumpas, **E.I. Rigopoulou**, G.N. Dalekos, D. Verganis, D.P. Bogdanos. Investigation of molecular mimicry and immunological cross-reactivity as mechanism responsible for the presence of anti-Ro52 antibodies in primary biliary cirrhosis.
59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, 31 October-4 November 2008

40. P. Pavlidis, M. Mytilinaiou, A. Koutsoumpas, **E.I. Rigopoulou**, D. Vergani, DP. Bogdanos. The role of herpes simplex virus type 1 in the induction of promyelocytic leukemia specific responses in primary biliary responses.
60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, 30 October-3November 2009
41. M. Mytilinaiou, A. Pares, ES. Spyrou, **E.I. Rigopoulou**, GN. Dalekos, D. Vergani, DP. Bogdanos. Diagnostic and clinical significance of anti-Ro52 antibodies in 609 samples with primary biliary cirrhosis from UK, Spain and Greece.
60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, 30 October-3November 2009
42. Athanasios Mavropoulos, **E.I. Rigopoulou** and D.P Bogdanos. Direct analysis of p38 MAPK phosphorylation and intracellular cytokine expression in rare human natural killer sub-populations by flow cytometry. *8th International Congress on Autoimmunity, 2010 Granada, Spain*
43. M. Mytilinaiou, L. Komorowski, **E.I. Rigopoulou**, A. Janssen, C. Probst, D. Vergani, DP. Bogdanos. F1F0-atpase as an autoantigenic target in patients with anti-mitochondrial antibody negative primary biliary cirrhosis.
61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, 29 October-2November 2010
44. K. Zachou, N. Gatselis, G. Papadamou, **E.I. Rigopoulou**, G.N. Dalekos. Mycophenolate for Autoimmune Hepatitis treatment: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.
46th Annual Meeting of the European Association of the Study of the Liver (EASL), Berlin, 30 March- 3April 2011 (αναρτημένη ανακοίνωση)
Και 10th Cogress of the European Federation of Internal Medicine, Athens 5-8 October 2011
45. Hepatocellular carcinoma: Clinical characteristics of the disease in Central Greece. Eriola Koumati, Aggelos Stefos, Kalliopi Zachou, Georgia Papadamou, **Eirini I. Rigopoulou**, George N. Dalekos.
10th Cogress of the European Federation of Internal Medicine, Athens 5-8 October 2011
46. Epidemiological characteristics and buerden of alcoholic liver disease in Central Greece. Aggelos Stefos, Kalliopi Zachou, Gerogia Papadamou, **E.I. Rigopoulou**, George N. Dalekos.
10th Cogress of the European Federation of Internal Medicine, Athens 5-8 October 2011
47. C. Liaskos, M. Mytilinaiou, A. Grammatikopoulos, D. Smyk, T. Orfanidou, A. Mavropoulos, G. Norman, **E.I. Rigopoulou**, G. Mieli-Vergani, D.P. Bogdanos, D. Vergani. New sensitive technique for the detection of anti-smooth muscle antibodies in autoimmune hepatitis.
63rd Annual Meeting of the American Association for the Study of Liver Diseases, 2012 Boston, USA
48. Athanasios Mavropoulos, **E.I. Rigopoulou**, D. Vergani and D.P Bogdanos. Flow cytometric analysis of p38 MAPK phosphorylation in peripheral CD56+ subsets-Relevance to immune mediated liver pathology.
47th Annual Meeting of the European Association of the Study of the Liver (EASL), Barcelona 18-22 April 2012

49. Autoimmune hepatitis natural history: a single Greek center experience focused on long-term effect of mycophenolate mofetil as first line treatment. K. Zachou, N. Gatselis, S. Gabeta, A. Saitis, G. Papadamou, **E.I. Rigopoulou**, G.K. Koukoulis, G.N. Dalekos
64th Annual Meeting of the American Association for the Study of Liver Diseases, 2013, Washington 7-11 November 2013
50. Longitudinal determination of IgA isotype-specific antibodies targeting the major recombinant mitochondrial antigens in patients with primary biliary cirrhosis. E. Spyrou, L.Komorowski, C. Probst, **E.I. Rigopoulou**, DP. Bogdanos, GN. Dalekos
64th Annual Meeting of the American Association for the Study of Liver Diseases, 2013, Washington 7-11 November 2013
51. Athanasios Mavropoulos, T. Simopoulou, C. Liaskos, E. Georgiou, C. Katsiari, **E.I Rigopoulou**, D.P Bogdanos and L.I Sakkas. CD56+CD7+CD11c+ (NK/DC) cell imbalance in patients with autoimmune rheumatic diseases. *9th International Congress on Autoimmunity, 2014, Nice, France*
52. Athanasios Mavropoulos, C. Liaskos, L.I Sakkas, D.P Bogdanos and **E.I Rigopoulou**. Phospho-p38 MAPK positive CD56+ subsets expressing IL-10 in autoimmune rheumatic diseases. *9th International Congress on Autoimmunity, 2014, Nice, France*
53. C. Liaskos, A. Vrana, T. Simopoulou, Athanasios Mavropoulos, M. Mytilinaiou, **E.I. Rigopoulou**, D.P Bogdanos and L.I Sakkas. Is there any role for *Helicobacter Pylori* in the pathogenesis of systemic sclerosis. *9th International Congress on Autoimmunity, 2014, Nice, France*